Neurana Pharmaceuticals

Pioneering new solutions for acute muscle spasms since 2013.

General Information
Company Name
Neurana Pharmaceuticals
Founded Year
2013
Location (Offices)
Founders / Decision Makers
Number of Employees
-
Industries
Biotechnology, Health Care, Pharmaceutical
Funding Stage
Series A
Social Media

Neurana Pharmaceuticals - Company Profile

Neurana Pharmaceuticals, a biotechnology company, has been revolutionizing the treatment of acute muscle spasms since its establishment in 2013. The California-based company has attracted significant attention, securing a noteworthy $60.00M Series A investment on 08 May 2018 from a group of prominent investors including H.I.G. BioHealth Partners, Longitude Capital, New Leaf Venture Partners, Sofinnova Investments, and MagnaSci Ventures. Specializing in the Biotechnology, Health Care, and Pharmaceutical sectors, Neurana Pharmaceuticals is committed to developing an innovative solution for acute muscle spasms, displaying considerable promise for the future of medical treatment.

Taxonomy: pharmaceuticals, acute muscle spasms, novel treatment, drug development, California, United States

Funding Rounds & Investors of Neurana Pharmaceuticals (1)

View All
Funding Stage Amount No. Investors Investors Date
Series A $60.00M 5 08 May 2018

Latest News of Neurana Pharmaceuticals

View All

No recent news or press coverage available for Neurana Pharmaceuticals.

Similar Companies to Neurana Pharmaceuticals

View All
KDDB General Trading & Contracting Co. W.L.L - Similar company to Neurana Pharmaceuticals
KDDB General Trading & Contracting Co. W.L.L KDDB is a dynamic company focused on providing engineering solutions which meet client’s needs in all Feilds,